recombinant tissue plasminogen activator

Phase 3Small molecule

recombinant tissue plasminogen activator is one of 146 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

145

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Venous ThrombosisActive, not recruiting

HemorrhageActive, not recruiting

Pulmonary EmbolismActive, not recruiting

Ischemic StrokeActive, not recruiting

StrokePhase 2

Active, not recruiting

Venous ThrombosisPhase 3

Active, not recruiting

HemorrhagePhase 2

Active, not recruiting

Pulmonary EmbolismPhase 3

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

recombinant tissue plasminogen activator

BBoston Scientific Corporation

Phase 3

2 2

Savella

AbbVie

Preclinical

1 3

Proamatine

Repatha

Pradaxa

3 6

Botox

RRevance Therapeutics, Inc.

Preclinical

2 7

Zantac 150

CChattem

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Direct Anticoagulant

Bayer

Preclinical

3 10

Anticoagulants

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Embolism4 trials

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism

Completed·BBoston Scientific Corporation·Phase 4·NCT02396758·131 enrolled

Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD

Unknown status·—·Phase 4·NCT01531829·460 enrolled

Thrombolysis Endovascular Treatment of Pulmonary Embolism

Completed·—·Phase 3·NCT03966079·50 enrolled

Show 1 more trial

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

Completed·BBoston Scientific Corporation·Phase 3·NCT01513759·150 enrolled

Stroke2 trials

Interventional Management of Stroke (IMS) II Study

Completed·UUniversity of Cincinnati·Phase 2·NCT00243906·81 enrolled

Safety and Efficacy of the Penumbra™ System in Acute Middle Cerebral Artery (MCA) Stroke

Withdrawn·HHospital de Clinicas de Porto Alegre·Phase 2·NCT01133223

Venous thrombosis2 trials

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Completed·WWashington University School of Medicine·Phase 3·NCT00790335·692 enrolled

Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial

Withdrawn·UUniversity of Colorado, Denver·Phase 3·NCT02767232

Thrombectomy1 trial

Direct Mechanical Thrombectomy Versus Bridging Therapy

Completed·—·Phase 4·NCT05155540·51 enrolled

Metastatic Cancer1 trial

In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer

Completed·NNorthwestern University·Phase 1/2·NCT00086723

3 more indications

Treatment1 trial

Treatment for Blood Clots in the Veins of the Legs

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00001713·20 enrolled

Hemorrhage1 trial

Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage

Completed·JJohns Hopkins University·Phase 2·NCT00029315·30 enrolled

Ischemic stroke1 trial

Sonothrombolysis Potentiated by Microbubbles for Acute Ischemic Stroke

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 2·NCT01678495·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for recombinant tissue plasminogen activator. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant tissue plasminogen activator compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant tissue plasminogen activator. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boston Scientific Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBoston Scientific Corporation

recombinant tissue plasminogen activator

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pulmonary Embolism4 trials

Stroke2 trials

Venous thrombosis2 trials

Thrombectomy1 trial

Metastatic Cancer1 trial

Treatment1 trial

Hemorrhage1 trial

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News